冠状动脉疾病和心力衰竭:医疗管理和未来的方向
Prem N Patel1, Michael C Poliner1, Eduardo Bossone2
1Department of Internal Medicine, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, 3rd Floor, Columbus, OH 43210-1267, USA.
Heart failure clinics
|March 19, 2025
概括
冠状动脉疾病 (CAD) 显著导致心力衰竭 (HF). 有效的管理涉及药物,设备和再血管化,以预防不良结果并改善患者的生存率.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 冠状动脉疾病管理
背景情况:
- 冠状动脉疾病 (CAD) 是心力衰竭 (HF) 的首要原因.
- 管理CAD对于减少HF相关的发病率和死亡率至关重要.
- 治疗策略旨在预防疾病进展和心脏不良事件.
研究的目的:
- 审查目前对HF患者的CAD的治疗策略.
- 讨论在这个患者群体中再血管化的作用.
- 为突出CAD和HF的新兴治疗方法.
主要方法:
- 对当前指导方针和临床试验的文献综述.
- 对药理学,基于设备和重血管化的方法进行分析.
- 讨论对外科候选人的风险益处评估.
主要成果:
- 药物治疗,电生理学装置和冠状动脉复血管化是关键干预措施.
- 再血管化策略需要个性化风险/益处评估.
- 新的药理学药剂正在开发中.
结论:
- 对CAD和HF的综合管理对于最佳的患者结果至关重要.
- 个性化治疗方法,包括再血管化,至关重要.
- 目前正在进行的研究有望为CAD和HF提供新的治疗选择.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
431
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
431
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K


